Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Article ID	Journal	Published Year	Pages	File Type
5577891	Cor et Vasa	2017	15 Pages	PDF

Keywords

CTRCD LMWH INR VTE LVEF BNP ARB ACE CMR TKI T-DM1 VKA NOAC HER2 VHD vitamin K antagonist Myocardial infarction angiotensin-converting enzyme (ACE) inhibitors Myocardial dysfunction Electrocardiography ECG Left ventricular Peripheral artery disease coronary artery disease cardiovascular disease valvular heart disease Venous thromboembolism Early detection cardiovascular magnetic resonance CVD Cancer therapy Cardiotoxicity Chemotherapy CAD Vascular endothelial growth factor Vascular Endothelial Growth Factor (VEGF)Cardio-oncology Lapatinib angiotensin II receptor blockers heart failure International Normalized Ratio Surveillance Low molecular weight heparin PAD B-type natriuretic peptide left ventricular ejection fraction Human epidermal growth factor receptor 2

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Authors

Hana Skalicka, Radek Pudil, Pavel Gregor,